A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease.

MLA

Galasko, Douglas, et al. “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen in Subjects with Early Alzheimer’s Disease.” Alzheimer’s Research & Therapy, vol. 16, no. 1, July 2024, p. 151. EBSCOhost, https://doi.org/10.1186/s13195-024-01490-z.

APA

Galasko, D., Farlow, M. R., Lucey, B. P., Honig, L. S., Elbert, D., Bateman, R., Momper, J., Thomas, R. G., Rissman, R. A., Pa, J., Aslanyan, V., Balasubramanian, A., West, T., Maccecchini, M., & Feldman, H. H. (2024). A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease. Alzheimer’s Research & Therapy, 16(1), 151. https://doi.org/10.1186/s13195-024-01490-z

Chicago

Galasko, Douglas, Martin R Farlow, Brendan P Lucey, Lawrence S Honig, Donald Elbert, Randall Bateman, Jeremiah Momper, et al. 2024. “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen in Subjects with Early Alzheimer’s Disease.” Alzheimer’s Research & Therapy 16 (1): 151. doi:10.1186/s13195-024-01490-z.